secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001411685-24-000051
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen Q2 FY2025 net loss $13.0M; Phase 3 SAD trials on track for 2025 data
-----------------------------------------------------------------------------

- Net loss of $13.0M for Q2 ended Sep 30, 2024 vs $6.6M a year ago, driven by higher R&D costs.
- R&D expense $10.2M (up from $3.9M) due to fasedienol PALISADE Phase 3 program costs.
- Cash, cash equivalents and marketable securities $97.6M as of Sep 30, 2024.
- PALISADE-3 and PALISADE-4 Phase 3 trials for fasedienol in social anxiety disorder actively recruiting; top-line results expected in 2025.
- Itruvone Phase 2B prep for MDD and PH80 IND-enabling program for menopausal hot flashes ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000141168524000051/0001411685-24-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000141168524000051/vtgn-20241107.htm
  HTML page:      https://secwatch.observer/filing/0001411685-24-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer